Regeneron Pharmaceuticals (REGN) DIvidends Date & History

Key Takeaways

• REGN introduced quarterly dividends in 2025 with an annual payout of $3.76 per share.
• Current dividend yield stands at approximately 0.48% based on recent share prices.
• Payout ratio remains very low at around 9%, indicating excellent earnings coverage.
• The company has increased its dividend once, marking a short but positive growth streak.
• Free cash flow comfortably supports the dividend, supporting long-term sustainability.
• REGN appeals primarily to growth-oriented investors seeking modest income.

Dividend Overview

Regeneron Pharmaceuticals (REGN) began paying dividends in early 2025 after years of reinvesting in research and development. The company distributes dividends quarterly, with the most recent quarterly payment set at $0.94 per share. This translates to an annualized dividend of $3.76 per share and a yield near 0.48%. REGN fits the profile of a new dividend payer with a modest yield rather than a high-yield or established dividend growth stock. The low payout leaves substantial room for future increases while funding ongoing innovation in biotechnology.

Dividend History and Growth

REGN initiated regular quarterly dividends in 2025. Payments started at $0.88 per share and rose to $0.94 in early 2026, representing a 6.82% increase. The company has now raised its dividend once, establishing a one-year growth streak. Prior to 2025, REGN did not pay dividends, focusing instead on pipeline development and share repurchases. The recent policy shift reflects strong cash generation from approved products such as EYLEA and Dupixent.

Dividend Sustainability and Payout Ratio

The dividend appears highly sustainable. REGN’s payout ratio of approximately 9% shows that earnings cover the dividend many times over. Free cash flow also provides ample coverage, allowing the company to maintain payments even during periods of higher research spending. Debt levels remain manageable for a biotechnology firm of its size, and consistent profitability supports continued distributions. With a conservative payout, REGN retains significant capital for growth initiatives.

Dividend Compared to Industry Peers

Within the biotechnology sector, REGN’s yield of 0.48% is below peers such as Amgen (AMGN) at roughly 2.6% and Novartis (NVS) at about 3.4%. Many established biopharma companies offer higher yields, while pure-play innovators often pay nothing. REGN’s profile aligns more closely with growth-focused peers that have only recently begun returning capital to shareholders.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Visit the AI Screener to explore opportunities.

Is This Stock Attractive for Dividend Investors?

REGN may suit long-term growth investors who value a conservative entry into dividend-paying stocks. The low yield and modest payout ratio appeal to those prioritizing capital appreciation and reinvestment over immediate income. Income-focused investors seeking higher current yields might find REGN less compelling compared with higher-yielding sector peers. Conservative dividend investors could view the strong earnings coverage and recent initiation as positive signs of financial maturity, while dividend growth investors may monitor future increases. The stock offers a balanced but secondary role in a diversified income portfolio.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations